Navigation Links
Biomira Inc. receives Nasdaq delisting notification
Date:11/5/2007

s goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws in the United States and Canada. Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to compliance by either Biomira or Oncothyreon with applicable Nasdaq listing requirements; the impact of the proposed effective reverse stock split on compliance with Nasdaq listing requirements; benefits currently anticipated to be derived from the proposed reincorporation transaction; and Biomira's business, including, without limitation, statements related to our agreements with Merck KGaA, the therapeutic and commercial potential of Stimuvax and other drug candidates in our clinical development pipeline, benefits anticipated from the acquisition of ProlX, future clinical development plans, the details of our planned clinical trials, the regulatory approval process and the general economic environment. A number of factors could cause actual results or events to differ materially from those anticipated by forward-looking statements. In particular, neither Biomira nor Oncothyreon can predict whether the conditions to completion of the reincorporation, including shareholder and judicial approvals, will be obtained. In addition, even if the reincorporation and the associated effective reverse stock split are approved and implemented, neither Biomira nor Oncothyreon can provide any assurances that they will continue to satisfy Nasdaq listing requirements. The business of Biomira and, assuming completion of the arrangement, the business of Oncothyreon are subject to numerous risks and uncertainties associated with biopharmaceutical development companies, including risks relating to the results of clin
'/>"/>

SOURCE Biomira Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Biomira Announces Plan to Reincorporate in the United States
2. Biomira announces plan to change name to Oncothyreon
3. Biomira to present at the BIO InvestorForum 2007
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... stock of United Kingdom -based Lab ... culture media and diagnostic systems. Lab ... a leading provider of microbial testing and diagnostic products ... markets. The company currently sells into more than 70 ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a ... the relationship of genetics and hypertension at the International Academy of Cardiology ... British Columbia, Canada. The event, which boasts an extensive overview of the latest ...
(Date:8/26/2015)... -- The Diabetes Research Institute (DRI), a Center of ... of Medicine, announced today that the first patient ... first time a novel transplant technique for insulin-producing ... I/II study builds upon decades of progress in ... step toward the development of the DRI BioHub, ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... , BEIJING, June 8 /PRNewswire-Asia/ -- Sinovac ... provider of vaccines in China, announced today that it,begins the production ... received from US CDC and was delivered to the company on ... Chairman, President and CEO of Sinovac, commented, ,In,the midst of a ...
... Offering AccuVein,s AV300 Hand-Held Vein Illumination Device to Membership , ... AccuVein LLC today announced a three year agreement with ... hand-held, non-contact vein illumination device to its members. The ... skin revealing vein position to help the healthcare professional locate ...
... Pasteuria Bioscience announced that it has received registration from ... usgae . This is a critical step towards the ... prevalent in soil that have long been recognized as promising ... , "We,re very pleased to receive this EPA registration," said ...
Cached Biology Technology:Sinovac Begins the Production of Influenza A (H1N1) Vaccine 2Sinovac Begins the Production of Influenza A (H1N1) Vaccine 3AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet 2Pasteuria Bioscience Receives EPA Registration for Nematode Control 2
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... Colorado (CU) has signed exclusive, worldwide licensing and ... Ltd to develop an enzyme replacement therapy for ... metabolic disease that is often fatal at a ... and includes sponsored-research funding by OT to continue ...
... during a record-setting expedition have yielded new insights about ... the cold, dark, and highly pressurized habitats of the ... Natalya Gallo of Scripps Institution of Oceanography at UC ... CHALLENGE expedition, a project led by James Cameron in ...
... virologist Masahiro Niikura and his doctoral student Nicole Bance are ... new class of molecular compounds capable of killing the influenza ... of a good thing can be a killer, the scientists ... is key to how influenza replicates and spreads. , ...
Cached Biology News:University of Colorado and Orphan Technologies sign agreement 2University of Colorado and Orphan Technologies sign agreement 3Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 2Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 3Influenza study: Meet virus' new enemy 2
capacity 250 mL...
... to MSY2/YBOX2 ( Abpromise for ... Antigen: Synthetic peptide derived from ... of human YBX2. (Note: the ... Entrez ...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z35,347-7) or ...
Standard Fluka For microscopy (Bact., Hist.)...
Biology Products: